Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for...

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Sodium-glucose co-transporter 2 (SGLT2) inhibitors demonstrate efficacy in reducing clinical events in heart failure (HF).
• Benefits are observed early and are sustained, irrespective of ejection fraction, diabetes, or care setting.
• SGLT2 inhibitors are becoming a cornerstone of modern foundational HF therapy.

Purpose of the Study:

• To provide an up-to-date review of current evidence on SGLT2 inhibitors in HF.
• To offer a practical guide for clinicians on prescribing SGLT2 inhibitors for HF patients.
• To highlight key aspects of patient selection, treatment initiation, dosing, and adverse effect management.

Main Methods:

• Review of current scientific literature and clinical trial data.
• Synthesis of evidence regarding the efficacy and safety of SGLT2 inhibitors in HF.
• Development of practical recommendations for clinical application.

Main Results:

• SGLT2 inhibitors provide substantial risk reduction for clinical events in HF patients.
• Consistent benefits are observed across diverse patient subgroups.
• Effective implementation requires careful patient selection and titration.

Conclusions:

• Clinicians must be familiar with SGLT2 inhibitors for optimal HF management.
• Proper understanding facilitates effective implementation and mitigation of potential adverse effects.
• SGLT2 inhibitors represent a vital therapeutic option for heart failure.